(PharmaNewsWire.Com, January 22, 2018 ) The Global Bleeding Disorders Treatment Market was worth USD 10.33 billion in 2016 and is estimated to be growing at a CAGR of 7.90%, to reach USD 15.11 billion by 2021. The market is showcasing evident potential in the mentioned forecasting period. A bleeding disorder is a condition in which blood clotting (also called coagulation) doesn’t take place properly in case of any wound or any cut which might lead to some serious problem because of too much loss of blood from the body.
There are many type of Bleeding Disorders, but the most common ones seen are Hemophilia A, Hemophilia B and von Willebrand Disease (vWD). A bleeding Disorder is generally diagnosed by any of these three methods: Complete Blood Count (CBC), Platelet Aggregation Test and bleeding time. There are various treatment methods depending on the type of bleeding disorder and its severity. Treatments include Iron Supplementation pills, Blood transfusion and other methods.
With careless lifestyle of teenagers and not taking care of their diet, iron deficiency in their body can take place easily, which is the root cause for bleeding disorders. Blood disorder cases are increasing worldwide at a very fast rate also because of the adulteration of food. Also, the fact that most of the bleeding disorders are inherited and cannot be completely cured is also driving this market. On the other hand, factors such as, high cost of treatment including medication and lack of skilled practitioners to cure these type of disorders are challenging this market.
The Global market for Bleeding Disorders Treatment is broadly categorized by Drug Class and by Disorder Type. On the basis of Drug Class, it is further sub-categorized into Fibrin Sealant, Desmopressin, Antibrinolytics, Recombinant Coagulation Factor Concentrates and Plasma Derived Coagulation Factor Concentrates. On the basis of disorder type, it is sub-categorized into Hemophilia A, Hemophilia B ad vWD. The recombinant coagulation factor concentrates segment is expected to grow the fastest in the mentioned forecast period. This is because of the increased R&D in this market and increasing focus of pharmaceutical companies on recombinant products.
Geographically, global market is further sub-categorized into North America, Latin America, Middle East & Africa, Asia-Pacific and Europe. For the upcoming years, Asia-Pacific is expected to grow the fastest in this market followed by Latin America. This can be attributed to the fact that local governments are becoming more concerned about the healthcare in these regions and increasing per capita income in these regions. North America has the biggest market share among all the regions.
Some of the major companies dominating the market, by their products and services include CSL Behring, Pfizer Inc., Novo Nordisk, Bayer AG, Biogen Inc., Shire Plc., Medline Plus, Janssen Global Services, LLC and Grifos SA.
About Us: Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialties with competitive pricing options.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
